Application of geniposide in preparation of medicine for treating asthenospermia

A technology for geniposide and asthenozoospermia, applied in the field of reproductive system diseases, to achieve the effect of improving excessive apoptosis

Active Publication Date: 2021-12-10
NINGXIA MEDICAL UNIV
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no literature report about its role in the treatment of oligoasthenospermia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of geniposide in preparation of medicine for treating asthenospermia
  • Application of geniposide in preparation of medicine for treating asthenospermia
  • Application of geniposide in preparation of medicine for treating asthenospermia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] The application of geniposide in the preparation of medicine for treating oligoasthenospermia, wherein the single application dose of geniposide is 6.25 mg / kg for mice, and the dosage form of the medicine is an oral dosage form.

Embodiment 2

[0036] The application of geniposide in the preparation of medicine for treating oligoasthenospermia, wherein the single application dose of geniposide is 12.5 mg / kg for mice, and the dosage form of the medicine is oral dosage form.

Embodiment 3

[0038] The application of geniposide in the preparation of medicine for treating oligoasthenospermia, wherein, the single application dose of geniposide is 25 mg / kg for mice, and the dosage form of the medicine is an oral dosage form.

[0039]The following animal experiment has further illustrated the effect of above-mentioned embodiment 1 to 3:

[0040] 1. Experimental materials

[0041] 1.1 Animal handling

[0042] SPF-grade ICR male adult mice weighing between 23-27 g were bred by the Experimental Animal Center of Ningxia Medical University (animal incubation batch number: SCXK (Ning) 2017-0001). Animals were fed according to the experimental animal feeding standards, and the feeding room was artificially controlled to alternate day and night for 12 hours, and the mice drank water freely.

[0043] 1.2 Experimental drugs and instruments

[0044] The main drugs and reagents that will be involved in this experiment include: geniposide (purchased from Shanghai Yuanye Biologi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of geniposide in preparation of a medicine for treating asthenospermia. Experimental results show that the geniposide can significantly improve the sperm quantity and activity and reduce the sperm malformation rate, can significantly inhibit endoplasmic reticulum stress inside testis, increase mitochondrial membrane potential, regulate expression of related proteins in testis tissues, and improve excessive apoptosis of spermatogenic cells.

Description

technical field [0001] The application belongs to the field of reproductive system diseases, and specifically, the application provides the use of geniposide in the preparation of medicaments for treating oligoasthenospermia. Background technique [0002] According to statistics, about 15%-20% of couples of childbearing age in the world have fertility problems, and the trend is increasing year by year. At least 50 percent of the men in couples who seek medical help for infertility to conceive naturally have sperm problems. At present, low sperm quality is the main cause of male infertility, of which oligoasthenospermia accounts for about 40%-75%. The etiology of oligoasthenozoospermia is complex, and it is often not caused by a single factor. It is mainly related to drugs, environment, heredity, endocrine, infection, disease and lifestyle. At present, the clinical treatment of oligoasthenospermia is often based on empirical treatment, but there is still a lack of effective...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P15/08
CPCA61K31/7048A61K9/0019A61K9/0053A61P15/08
Inventor 余建强叶瑞娟海冬梅杨佳美任佳玮池彦南刘宁马琳兰小兵杜娟
Owner NINGXIA MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products